MILWAUKEE, July 17, 2023 /PRNewswire/ -- Ademi LLP is investigating Pardes (Nasdaq:PRDS) for possible breaches of fiduciary duty and other violations of law in its transaction with MediPacific.
Read more at prnewswire.comShareholder Alert: Ademi LLP investigates whether Pardes Biosciences, Inc. has obtained a Fair Price in its transaction with MediPacific
PR Newswire -
Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here